- Conditions
- Herpes Labialis
- Interventions
- onabotulinumtoxinA, Bacteriostatic normal saline
- Drug · Other
- Lead sponsor
- DeNova Research
- Other
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–12
of 12
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Herpes Zoster, Shingles
- Interventions
- Amezosvatein Antigen High Dose Arm A, Amezosvatein Antigen Low Dose Arm B, Shingrix, Amezosvatein Adjuvant Dose Arm D, Amezosvatein Adjuvant Dose Arm F, Amezosvatein Adjuvant Dose Arm H, Amezosvatein Adjuvant Dose Arm J, Amezosvatein Adjuvant Dose Arm L
- Biological
- Lead sponsor
- Curevo Inc
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 1,516 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2032
- U.S. locations
- 14
- States / cities
- Tempe, Arizona • Coral Gables, Florida • Tampa, Florida + 11 more
- Conditions
- Herpes Simplex Virus Keratitis
- Interventions
- oral acyclovir 400 mg BID OR valacyclovir 500 mg qdaily, oral acyclovir 400 mg BID OR valacyclovir 500 mg qdaily + topical corticosteroid eye drops
- Drug
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 18 Years to 100 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Herpes Zoster, Postherpetic Neuralgia
- Interventions
- Varicella-zoster vaccine, Placebo
- Biological
- Lead sponsor
- US Department of Veterans Affairs
- Federal
- Eligibility
- 60 Years and older
- Enrollment
- 38,456 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 1998 – 2011
- U.S. locations
- 22
- States / cities
- Birmingham, Alabama • Palo Alto, California • San Diego, California + 19 more
- Conditions
- Genital Herpes Simplex Type 2
- Interventions
- BNT163, Placebo
- Biological · Other
- Lead sponsor
- BioNTech SE
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 318 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2026
- U.S. locations
- 6
- States / cities
- Tempe, Arizona • Chicago, Illinois • Raleigh, North Carolina + 3 more
- Conditions
- Adenovirus Infection, BK Virus Infection, Cytomegalovirus Infections, Epstein-Barr Virus Infections, Human Herpes Virus-6 Infection, JC Virus Infection
- Interventions
- Posoleucel (ALVR105)
- Biological
- Lead sponsor
- AlloVir
- Industry
- Eligibility
- 1 Year and older
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 16
- States / cities
- Birmingham, Alabama • Duarte, California • San Francisco, California + 12 more
- Conditions
- Shingles, Herpes Zoster, Postherpetic Neuralgia
- Interventions
- FV-100, valacyclovir
- Drug
- Lead sponsor
- ContraVir Pharmaceuticals, Inc.
- Industry
- Eligibility
- 30 Years and older
- Enrollment
- 237 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 1
- States / cities
- Webster, Texas
- Conditions
- Prophylaxis for Herpes Simplex
- Interventions
- Herpes simplex candidate vaccine- adjuvanted GSK 208141, Placebo
- Biological
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 7,460 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 1996 – 1999
- U.S. locations
- 36
- States / cities
- La Jolla, California • Middle Valley, California • San Diego, California + 31 more
- Conditions
- Herpes Simplex Infection
- Interventions
- HSV vaccine or SB208141, GSK Biologicals' glycoprotein D (gD)-Alum/3-deacylated form of Monophosphoryl Lipid A (MPL) candidate genital herpes vaccine, Havrix™, GlaxoSmithKline (GSK) Biologicals' licensed Hepatitis A vaccine
- Biological
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 30 Years · Female only
- Enrollment
- 8,323 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2003 – 2009
- U.S. locations
- 67
- States / cities
- Birmingham, Alabama • Chandler, Arizona • Mesa, Arizona + 56 more
- Conditions
- Herpes Simplex
- Interventions
- acyclovir sodium
- Drug
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 112 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2013
- U.S. locations
- 1
- States / cities
- Winston-Salem, North Carolina
- Conditions
- Adenovirus Infection, BK Virus Infection, Cytomegalovirus Infections, Epstein-Barr Virus Infections, Human Herpes Virus-6 Infection, JC Virus Infection
- Interventions
- Posoleucel (ALVR105), Placebo
- Biological
- Lead sponsor
- AlloVir
- Industry
- Eligibility
- Not listed
- Enrollment
- 451 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 35
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Duarte, California + 31 more
- Conditions
- Herpes Simplex
- Interventions
- Valaciclovir
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- Not listed
- Enrollment
- 180 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1997 – 2003
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland